Hedge fund
Logos Global Management LP
13F for June 30, 2026, filed August 14, 2026 · SEC CIK 1792126 · Holdings history from December 31, 2019
- Reported value
- $2.3bn 100% in companies we cover
- Positions we cover
- 66 Largest ERAS 9.6%
- Copy, a year
- −4.0% S&P 500 +14.6%
- Copy Sharpe ratio
- 0.03 S&P 500 0.66
Historical holdings
| Issuer | Class / type | Reported value | Quantity |
|---|---|---|---|
| ABIVAX SA00370M103 · ABVX | SPONSORED ADS | $136.5m | 1,024,000 |
| ACADIA PHARMACEUTICALS INC004225108 · ACAD | COM | $6.3m | 250,000 |
| ACHIEVE LIFE SCIENCE INC004468500 · ACHV | COM | $35.4m | 5,425,000 |
| ACLARIS THERAPEUTICS INC00461U105 · ACRS | COM | $1.1m | 200,000 |
| AMANAT ACQUISITION CORPG0375M101 | CL A ORD | $508,000 | 50,000 |
| AMYLYX PHARMACEUTICALS INC03237H101 · AMLX | COM | $6.3m | 350,000 |
| ANNEXON INC03589W102 · ANNX | COM | $8.6m | 1,500,000 |
| ARCUS BIOSCIENCES INC03969F109 · RCUS | COM | $20.0m | 650,000 |
| ARRIVENT BIOPHARMA INC04272N102 · AVBP | COM | $34.7m | 1,000,000 |
| AVALO THERAPEUTICS INC05338F306 · AVTX | COM NEW | $21.3m | 1,150,000 |
| BELITE BIO INC07782B104 · BLTE | SPONSORED ADS | $38.5m | 250,000 |
| BIONTECH SE09075V102 · BNTX | SPONSORED ADS | $94.4m | 1,015,000 |
| CELLDEX THERAPEUTICS INC NEW15117B202 · CLDX | COM NEW | $78.1m | 2,100,000 |
| CG ONCOLOGY INC156944100 · CGON | COM | $71.0m | 1,000,000 |
| COGENT BIOSCIENCES INC19240Q201 · COGT | COM | $34.8m | 900,000 |
| COMPASS PATHWAYS PLC20451W101 · CMPS | SPONSORED ADS | $31.8m | 2,250,000 |
| CRESCENT BIOPHARMA INC.G2545C104 · CBIO | COM | $34.2m | 1,900,000 |
| CRISPR THERAPEUTICS AGH17182108 · CRSP | NAMEN AKT | $16.4m | 300,000 |
| CYBIN INC23256X407 · HELP | COM NEW | $5.0m | 750,000 |
| DBV TECHNOLOGIES S A23306J309 · DBVT | SPONSORED ADS | $15.0m | 915,000 |
| DEFINIUM THERAPEUTICS INC24477V105 · DFTX | COM SHS | $3.8m | 80,000 |
| DESIGN THERAPEUTICS INC25056L103 · DSGN | COM | $43.4m | 3,000,000 |
| DIANTHUS THERAPEUTICS INC252828108 · DNTH | COM | $78.0m | 800,000 |
| DISC MEDICINE INC254604101 · IRON | COM | $64.0m | 875,000 |
| DYNE THERAPEUTICS INC26818M108 · DYN | COM | $56.6m | 2,550,000 |
| EDITAS MEDICINE INC28106W103 · EDIT | COM | $7.2m | 2,222,000 |
| ENLIVEN THERAPEUTICS INC29337E102 · ELVN | COM | $23.6m | 465,000 |
| ERASCA INC29479A108 · ERAS | COM | $222.6m | 12,150,000 |
| FAETH THERAPEUTICS INC81728A207 · FTH | COM NEW | $18.1m | 722,020 |
| FRACTYL HEALTH INC35168W103 · GUTS | COM | $794,400 | 1,000,000 |
| IDEAYA BIOSCIENCES INC45166A102 · IDYA | COM | $111.8m | 3,000,000 |
| IMMIX BIOPHARMA INC45258H106 · IMMX | COM | $10.3m | 1,000,000 |
| IMMUNOCORE HLDGS PLC45258D105 · IMCR | ADS | $19.1m | 600,000 |
| IMMUNOVANT INC45258J102 · IMVT | COM | $25.6m | 665,000 |
| JADE BIOSCIENCES INC008064206 · JBIO | COM NEW | $25.0m | 1,125,000 |
| JATT II ACQUISITION CORPG50765109 | ORD SHS | $1.1m | 100,000 |
| LB PHARMACEUTICALS INC50180M108 · LBRX | COM SHS | $19.0m | 585,000 |
| LONGEVERON INC54303L203 · LGVN | CL A NEW | $904,761 | 1,287,000 |
| MAZE THERAPEUTICS INC578784100 · MAZE | COM | $57.7m | 1,935,000 |
| MINERALYS THERAPEUTICS INC603170101 · MLYS | COM | $28.3m | 1,050,000 |
| MINERVA NEUROSCIENCES INC603380205 · NERV | COM NEW | $18.3m | 3,288,777 |
| MOONLAKE IMMUNOTHERAPEUTICS61559X104 · MLTX | CLASS A ORD | $52.1m | 2,675,000 |
| OCULAR THERAPEUTIX INC67576A100 · OCUL | COM | $52.0m | 5,300,000 |
| ODYSSEY THERAPEUTICS INC67613T104 · ODTX | COMMON STOCK | $9.8m | 521,736 |
| OLEMA PHARMACEUTICALS INC68062P106 · OLMA | COM | $40.1m | 3,208,875 |
| ONKURE THERAPEUTICS INC68277Q105 · OKUR | COM CL A | $4.4m | 963,855 |
| PALATIN TECHNOLOGIES INC696077601 · PTN | COM NEW | $1.4m | 130,000 |
| PARABILIS MEDICINES INC698955101 · PBLS | COM | $14.4m | 525,000 |
| PRAXIS PRECISION MEDICINES I74006W207 · PRAX | COM NEW | $87.0m | 260,000 |
| Q32 BIO INC746964105 · QTTB | COM | $10.2m | 800,000 |
| RELAY THERAPEUTICS INC75943R102 · RLAY | COM | $6.5m | 350,000 |
| REPLIMUNE GROUP INC76029N106 · REPL | COM | $27.7m | 2,500,000 |
| RESEARCH ALLIANCE CORP IIIG75226103 · RACC | ORD SHS CL A | $1.1m | 100,000 |
| REVOLUTION MEDICINES INC76155X100 · RVMD | COM | $131.1m | 700,000 |
| RHYTHM PHARMACEUTICALS INC76243J105 · RYTM | COM | $13.9m | 125,000 |
| SCHOLAR ROCK HLDG CORP80706P103 · SRRK | COM | $11.0m | 200,000 |
| SEPTERNA INC81734D104 · SEPN | COM | $788,623 | 23,548 |
| STRUCTURE THERAPEUTICS INC86366E106 · GPCR | SPONSORED ADS | $26.8m | 500,000 |
| SUMMIT THERAPEUTICS INC86627T108 · SMMT | COM | $19.7m | 1,350,000 |
| TANGO THERAPEUTICS INC87583X109 · TNGX | COM | $89.1m | 2,850,000 |
| TENAX THERAPEUTICS INC88032L605 · TENX | COM NEW | $4.4m | 300,000 |
| TREVI THERAPEUTICS INC89532M101 · TRVI | COM | $35.1m | 1,880,000 |
| UNICYCIVE THERAPEUTICS INC90466Y202 · UNCY | COM NEW | $2.2m | 473,563 |
| UNIQURE NVN90064101 · QURE | SHS | $1.4m | 30,000 |
| VERA THERAPEUTICS INC92337R101 · VERA | CL A | $94.4m | 2,200,000 |
| VERADERMICS INC922967104 · MANE | COMMON STOCK | $22.1m | 180,000 |
| VOR BIOPHARMA INC929033207 · VOR | COM NEW | $12.0m | 650,000 |
| XENON PHARMACEUTICALS INC98420N105 · XENE | COM | $27.2m | 450,000 |
How copying its 13F would have done
Reported value by quarter
View chart data
| Period | Reported value |
|---|---|
| 2019-12-31 | $405.7M |
| 2020-03-31 | $262.9M |
| 2020-06-30 | $500.5M |
| 2020-09-30 | $781.4M |
| 2020-12-31 | $1.2B |
| 2021-03-31 | $1B |
| 2021-06-30 | $1.2B |
| 2021-09-30 | $1.4B |
| 2021-12-31 | $969.6M |
| 2022-03-31 | $771.3M |
| 2022-06-30 | $545.1M |
| 2022-09-30 | $813.4M |
| 2022-12-31 | $853.6M |
| 2023-03-31 | $698.7M |
| 2023-06-30 | $735.2M |
| 2023-09-30 | $749.5M |
| 2023-12-31 | $1.1B |
| 2024-03-31 | $1.2B |
| 2024-06-30 | $2.5B |
| 2024-09-30 | $926.8M |
| 2024-12-31 | $854.6M |
| 2025-03-31 | $562.5M |
| 2025-06-30 | $903.8M |
| 2025-09-30 | $1.1B |
| 2025-12-31 | $1.7B |
| 2026-03-31 | $2B |
| 2026-06-30 | $2.3B |
Latest covered holdings and moves
| Company | Share of portfolio | Value | Shares | Change in shares |
|---|---|---|---|---|
| ERASErasca, Inc. | 9.58% | $222.6m | 12.15M | +9.0% Added |
| ABVXAbivax S.a. | 5.87% | $136.5m | 1.02M | +51.7% Added |
| RVMDRevolution Medicines, Inc. | 5.64% | $131.1m | 700.0K | −65.0% Reduced |
| IDYAIdeaya Biosciences, Inc. | 4.81% | $111.8m | 3.00M | −13.0% Reduced |
| BNTXBiontech SE | 4.07% | $94.4m | 1.01M | New |
| VERAVera Therapeutics, Inc. | 4.06% | $94.4m | 2.20M | New |
| TNGXTango Therapeutics, Inc. | 3.83% | $89.1m | 2.85M | −5.0% Reduced |
| PRAXPraxis Precision Medicines, Inc. | 3.75% | $87.0m | 260.0K | −8.8% Reduced |
| CLDXCelldex Therapeutics, Inc. | 3.36% | $78.1m | 2.10M | +366.7% Added |
| DNTHDianthus Therapeutics, Inc. | 3.36% | $78.0m | 800.0K | +100.0% Added |
| CGONCG Oncology, Inc. | 3.06% | $71.0m | 1.00M | +73.9% Added |
| IRONDisc Medicine, Inc. | 2.75% | $64.0m | 875.0K | +56.2% Added |
| MAZEMaze Therapeutics, Inc. | 2.49% | $57.7m | 1.94M | +56.7% Added |
| DYNDyne Therapeutics, Inc. | 2.44% | $56.6m | 2.55M | +82.1% Added |
| MLTXMoonlake Immunotherapeutics | 2.24% | $52.1m | 2.67M | +78.3% Added |
| OCULOcular Therapeutix, Inc | 2.24% | $52.0m | 5.30M | +37.7% Added |
| DSGNDesign Therapeutics, Inc. | 1.87% | $43.4m | 3.00M | +53.8% Added |
| OLMAOlema Pharmaceuticals, Inc. | 1.73% | $40.1m | 3.21M | 0.0% |
| BLTEBelite BIO, Inc | 1.66% | $38.5m | 250.0K | New |
| ACHVAchieve Life Sciences, Inc. | 1.52% | $35.4m | 5.42M | New |
| TRVITrevi Therapeutics, Inc. | 1.51% | $35.1m | 1.88M | −21.7% Reduced |
| COGTCogent Biosciences, Inc. | 1.50% | $34.8m | 900.0K | New |
| AVBPArrivent Biopharma, Inc. | 1.50% | $34.7m | 1.00M | +185.7% Added |
| CBIOCrescent Biopharma, Inc. | 1.47% | $34.2m | 1.90M | +293.8% Added |
| CMPSCompass Pathways plc | 1.37% | $31.8m | 2.25M | New |
| MLYSMineralys Therapeutics, Inc. | 1.22% | $28.3m | 1.05M | New |
| REPLReplimune Group, Inc. | 1.19% | $27.7m | 2.50M | New |
| XENEXenon Pharmaceuticals Inc. | 1.17% | $27.2m | 450.0K | 0.0% |
| GPCRStructure Therapeutics Inc. | 1.16% | $26.8m | 500.0K | 0.0% |
| IMVTImmunovant, Inc. | 1.10% | $25.6m | 665.0K | −38.1% Reduced |
| JBIOJade Biosciences, Inc. | 1.08% | $25.0m | 1.13M | +181.2% Added |
| ELVNEnliven Therapeutics, Inc. | 1.02% | $23.6m | 465.0K | −13.9% Reduced |
| MANEVeradermics, Inc | 0.95% | $22.1m | 180.0K | +620.0% Added |
| AVTXAvalo Therapeutics, Inc. | 0.92% | $21.3m | 1.15M | +283.3% Added |
| RCUSArcus Biosciences, Inc. | 0.86% | $20.0m | 650.0K | −45.8% Reduced |
| SMMTSummit Therapeutics Inc. | 0.85% | $19.7m | 1.35M | New |
| IMCRImmunocore Holdings plc | 0.82% | $19.1m | 600.0K | −60.0% Reduced |
| LBRXLB Pharmaceuticals Inc | 0.82% | $19.0m | 585.0K | −36.1% Reduced |
| NERVMinerva Neurosciences, Inc. | 0.79% | $18.3m | 3.29M | +2.3% Added |
| FTHFaeth Therapeutics, Inc. | 0.78% | $18.1m | 722.0K | +2306.7% Added |
| CRSPCrispr Therapeutics AG | 0.70% | $16.4m | 300.0K | New |
| DBVTDBV Technologies S.a. | 0.65% | $15.0m | 915.0K | New |
| PBLSParabilis Medicines, Inc. | 0.62% | $14.4m | 525.0K | New |
| RYTMRhythm Pharmaceuticals, Inc. | 0.60% | $13.9m | 125.0K | −72.2% Reduced |
| VORVor Biopharma Inc. | 0.52% | $12.0m | 650.0K | −13.3% Reduced |
| SRRKScholar Rock Holding Corp | 0.47% | $11.0m | 200.0K | New |
| IMMXImmix Biopharma, Inc. | 0.44% | $10.3m | 1.00M | −18.4% Reduced |
| QTTBQ32 Bio Inc. | 0.44% | $10.2m | 800.0K | New |
| ODTXOdyssey Therapeutics, Inc. | 0.42% | $9.8m | 521.7K | New |
| ANNXAnnexon, Inc. | 0.37% | $8.6m | 1.50M | New |
| EDITEditas Medicine, Inc. | 0.31% | $7.2m | 2.22M | New |
| RLAYRelay Therapeutics, Inc. | 0.28% | $6.5m | 350.0K | −53.3% Reduced |
| ACADAcadia Pharmaceuticals Inc | 0.27% | $6.3m | 250.0K | −66.7% Reduced |
| AMLXAmylyx Pharmaceuticals, Inc. | 0.27% | $6.3m | 350.0K | −50.0% Reduced |
| HELPHelus Pharma Inc. | 0.21% | $5.0m | 750.0K | New |
| OKUROnkure Therapeutics, Inc. | 0.19% | $4.4m | 963.9K | New |
| TENXTenax Therapeutics, Inc. | 0.19% | $4.4m | 300.0K | −52.0% Reduced |
| DFTXDefinium Therapeutics, Inc. | 0.16% | $3.8m | 80.0K | New |
| UNCYUnicycive Therapeutics, Inc. | 0.10% | $2.2m | 473.6K | 0.0% |
| PTNPalatin Technologies Inc | 0.06% | $1.4m | 130.0K | −7.1% Reduced |
| QUREUniqure N.V. | 0.06% | $1.4m | 30.0K | New |
| RACCResearch Alliance Corp III | 0.05% | $1.1m | 100.0K | New |
| ACRSAclaris Therapeutics, Inc. | 0.05% | $1.1m | 200.0K | −60.0% Reduced |
| LGVNLongeveron Inc. | 0.04% | $904,761 | 1.29M | New |
| GUTSFractyl Health, Inc. | 0.03% | $794,400 | 1.00M | 0.0% |
| SEPNSepterna, Inc. | 0.03% | $788,623 | 23.5K | 0.0% |
| Company | Bought (value) | Shares |
|---|---|---|
| BNTXBiontech SE | $94.4m | 1.01M |
| VERAVera Therapeutics, Inc. | $94.4m | 2.20M |
| CLDXCelldex Therapeutics, Inc. | $61.4m | 1.65M |
| ABVXAbivax S.a. | $46.5m | 349.0K |
| DNTHDianthus Therapeutics, Inc. | $39.0m | 400.0K |
| BLTEBelite BIO, Inc | $38.5m | 250.0K |
| ACHVAchieve Life Sciences, Inc. | $35.4m | 5.42M |
| COGTCogent Biosciences, Inc. | $34.8m | 900.0K |
| CMPSCompass Pathways plc | $31.8m | 2.25M |
| CGONCG Oncology, Inc. | $30.2m | 425.0K |
| MLYSMineralys Therapeutics, Inc. | $28.3m | 1.05M |
| REPLReplimune Group, Inc. | $27.7m | 2.50M |
| DYNDyne Therapeutics, Inc. | $25.5m | 1.15M |
| CBIOCrescent Biopharma, Inc. | $25.5m | 1.42M |
| IRONDisc Medicine, Inc. | $23.0m | 315.0K |
| Company | Sold (value) | Shares |
|---|---|---|
| RVMDRevolution Medicines, Inc. | −$243.5m | −1.30M |
| CYTKCytokinetics Inc | −$57.7m | −875.0K |
| UTHRUnited Therapeutics Corp | −$47.4m | −80.0K |
| MDGLMadrigal Pharmaceuticals, Inc. | −$44.5m | −85.0K |
| BIIBBiogen | −$36.7m | −200.0K |
| RYTMRhythm Pharmaceuticals, Inc. | −$36.1m | −325.0K |
| TYRATyra Biosciences, Inc. | −$32.6m | −850.0K |
| IMCRImmunocore Holdings plc | −$28.6m | −900.0K |
| NAMSNewamsterdam Pharma Co N.V. | −$19.2m | −600.0K |
| MIRMMirum Pharmaceuticals, Inc. | −$18.5m | −200.0K |
| PCVXVaxcyte, Inc. | −$17.4m | −300.0K |
| RCUSArcus Biosciences, Inc. | −$17.0m | −550.0K |
| IDYAIdeaya Biosciences, Inc. | −$16.8m | −450.0K |
| CMPXCompass Therapeutics, Inc. | −$16.7m | −3.15M |
| IMVTImmunovant, Inc. | −$15.8m | −410.0K |
| Company | Value last quarter | Shares |
|---|---|---|
| CYTKCytokinetics Inc | $57.7m | 875.0K |
| UTHRUnited Therapeutics Corp | $47.4m | 80.0K |
| MDGLMadrigal Pharmaceuticals, Inc. | $44.5m | 85.0K |
| BIIBBiogen | $36.7m | 200.0K |
| TYRATyra Biosciences, Inc. | $32.6m | 850.0K |
| NAMSNewamsterdam Pharma Co N.V. | $19.2m | 600.0K |
| MIRMMirum Pharmaceuticals, Inc. | $18.5m | 200.0K |
| PCVXVaxcyte, Inc. | $17.4m | 300.0K |
| CMPXCompass Therapeutics, Inc. | $16.7m | 3.15M |
| JANXJanux Therapeutics, Inc. | $13.9m | 1.00M |
| ALKSAlkermes plc. | $12.4m | 350.0K |
| ORICOric Pharmaceuticals, Inc. | $12.0m | 950.0K |
| CRVSCorvus Pharmaceuticals, Inc. | $6.6m | 450.0K |
| MGTXMeiragtx Holdings plc | $6.1m | 700.0K |
| VSTMVerastem, Inc. | $5.3m | 1.00M |
| IBIOIbio, Inc. | $2.5m | 1.30M |
| PHVSPharvaris N.V. | $1.8m | 65.0K |
| Period | Copy, a year | S&P 500 | Sharpe | S&P 500 | Biggest drop | Beta |
|---|---|---|---|---|---|---|
| Whole backtestFebruary 21, 2020 to November 2, 2026 | −4.0% | +14.6% | 0.03 | 0.66 | −82.5% | 1.07 |
| Last three yearsNovember 3, 2023 to November 2, 2026 | +19.8% | +21.8% | 0.55 | 1.16 | −49.1% | 1.28 |
| Last yearNovember 7, 2025 to November 2, 2026 | +40.0% | +14.2% | 0.98 | 0.84 | −26.2% | 1.26 |